Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 2/20 | 0.54 |
| ▸ | SRC | P12931 | 2/20 | 0.54 |
| ▸ | KDR | P35968 | 3/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | INSR | P06213 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.51 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.51 |
| ▸ | TNK2 | Q07912 | 7/20 | 0.50 |
| ▸ | RET | P07949 | 2/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 5/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.43 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.40 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6940080 | 0.89 | RAF1 (0.67) | RAF1SRCKDRABL1PDPK1 | |
| SCHEMBL11980650 | 0.87 | PIK3CA (0.55) | RAF1SRCKDRABL1PDPK1 | |
| SCHEMBL11980651 | 0.86 | CCNT1 (0.49) | RAF1SRCTNK2RETCDK9 | |
| SCHEMBL14536972 | 0.80 | RAF1 (0.79) | RAF1SRCKDRABL1PDPK1 | |
| SCHEMBL6942526 | 0.76 | PIK3CA (0.55) | RAF1SRCKDRABL1PDPK1 | |
| SCHEMBL6942533 | 0.75 | RAF1 (0.50) | RAF1SRCKDRABL1PDPK1 | |
| SCHEMBL8076281 | 0.72 | RAF1 (0.81) | RAF1SRCKDRABL1PDPK1 | |
| SCHEMBL11980639 | 0.72 | IGF1R (0.73) | RAF1SRCKDRABL1PDPK1 | |
| SCHEMBL593448 | 0.72 | RAF1 (0.82) | RAF1SRCKDRABL1PDPK1 | |
| SCHEMBL594970 | 0.72 | RAF1 (0.79) | RAF1SRCKDRABL1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586546-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120207767-A1 | Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors | OSI PHARMACEUTICALS, LLC. | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120207767-A1 | Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors | EGFR, ERBB2, MTOR | RAF1 70/4885SRC 15/4885KDR 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.